Biocon says its oral insulin is good for Type 2 diabetes

Mumbai: Biocon Ltd, the country's premier biotechnology company, today said the oral insulin IN-105 developed by the company is safe and well tolerated by patients.

The results of an ascending dose linearity study with the oral insulin drug (IN-105) were announced at the European Association for the Study of Diabetes (EASD) meeting in Rome on 8 September.

The study of the drug's tolerability involved dosing Type 2 diabetes subjects with single doses of 0 mg (placebo), 10 mg, 15 mg, 20 mg and 30 mg tablets of IN-105 in 5 separate periods before a mixed 600 kcal breakfast, the company said in a release.

The 2 hour postprandial glucose rise over baseline for the 10, 15, 20 and 30 mg doses were 15.3, 24.1, 31.3 and 49.5 mg/dL lower than the corresponding rise for placebo. There were no symptomatic hypoglycemic events observed at any of the doses.

The results showed that IN-105 is safe and well tolerated by Type 2 diabetic patients and is able to significantly drop 2-hour post-prandial glucose in a dose-related manner, the release said.

The oral insulin, which aims to be a needleless alternative to the injection, has advanced to late-stage trials, having shown promising results in the mid-stage studies in India.